BLUESTEM BRANDS, INC. 10,000,000 Shares of Common Stock Underwriting Agreement
Exhibit 1.1
10,000,000 Shares of Common Stock
[ ], 2011
Xxxxx Xxxxxxx & Co.
Xxxxx Fargo Securities, LLC
As Representatives of the
several Underwriters listed
in Schedule I hereto
c/o Xxxxx Xxxxxxx & Co.
000 Xxxxxxxx Xxxx
Xxxxxxxxxxx, Xxxxxxxxx 00000
Xxxxx Fargo Securities, LLC
As Representatives of the
several Underwriters listed
in Schedule I hereto
c/o Xxxxx Xxxxxxx & Co.
000 Xxxxxxxx Xxxx
Xxxxxxxxxxx, Xxxxxxxxx 00000
Ladies and Gentlemen:
Bluestem Brands, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to
the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you are acting
as representatives (the “Representatives”), an aggregate of 10,000,000 shares of common stock, par
value $0.00001 per share, of the Company (the “Underwritten Shares”). In addition, the Company
also proposes to sell, at the option of the Underwriters, up to an additional 1,500,000 shares of
common stock, par value $0.00001 per share, of the Company (the “Option Shares”). The Underwritten
Shares and the Option Shares are herein referred to as the “Shares”. The shares of common stock of
the Company to be outstanding after giving effect to the sale of the Shares are referred to herein
as the “Common Stock”.
The Company hereby confirms its agreement with the several Underwriters concerning the
purchase and sale of the Shares, as follows:
1. Registration Statement. The Company has prepared and filed with the Securities and
Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended, and the rules
and regulations of the Commission thereunder (collectively, the “Securities Act”), a registration
statement on Form S-1 (File No. 333-173668), including a prospectus, relating to the Shares. Such
registration statement, as amended at the time it became effective, including the information, if
any, deemed pursuant to Rule 430A, 430B or 430C under the Securities Act to be part of the
registration statement at the time of its effectiveness (“Rule 430 Information”), is referred to
herein as the “Registration Statement”; and as used herein, the term “Preliminary Prospectus” means
each prospectus included in such registration statement (and any amendments thereto) before
effectiveness, any prospectus filed with the Commission pursuant to Rule 424(a) under the
Securities Act and the prospectus included in the Registration Statement at the time of its
effectiveness that omits Rule 430 Information, and the term “Prospectus” means the prospectus in
the form first used (or made available upon request of purchasers pursuant to Rule 173 under the
Securities Act) in connection with confirmation of sales of the Shares. If the Company has
filed an abbreviated registration statement pursuant to Rule 462(b) under the Securities Act (the
“Rule 462 Registration Statement”), then any reference herein to the term “Registration Statement”
shall be deemed to include such Rule 462 Registration Statement. Capitalized terms used but not
defined herein shall have the meanings given to such terms in the Registration Statement and the
Prospectus.
At or prior to the Applicable Time (as defined below), the Company had prepared the following
information (collectively with the pricing information set forth on Annex B, the “Pricing
Disclosure Package”): a Preliminary Prospectus dated [ ], 2011 and each “free-writing
prospectus” (as defined pursuant to Rule 405 under the Securities Act) listed on Annex B hereto.
“Applicable Time” means [ ] [A/P].M., New York City time, on [ ], 2011.
2. Purchase of the Shares by the Underwriters. (a) On the basis of the
representations, warranties and agreements set forth herein, but subject to the terms and
conditions set forth herein, the Company agrees to issue and sell the Underwritten Shares to the
several Underwriters, and each Underwriter agrees, severally and not jointly, to purchase from the
Company the number of Underwritten Shares set forth opposite the name of such Underwriter in
Schedule I hereto. The purchase price for each Underwritten Share shall be $[ ] per share
(the “Purchase Price”). The obligation of each Underwriter to the Company shall be to purchase
from the Company the number of Underwritten Shares set forth opposite the name of such Underwriter
in Schedule I hereto. In making this Agreement, each Underwriter is contracting severally and not
jointly; except as provided in paragraph (e) of this Section 2 and in Section 10 hereof, the
agreement of each Underwriter is to purchase only the respective number of Underwritten Shares
specified in Schedule I.
In addition, the Company agrees to issue and sell the Option Shares to the several
Underwriters as provided in this Agreement, and the Underwriters, on the basis of the
representations, warranties and agreements set forth herein and subject to the conditions set forth
herein, shall have the option to purchase, severally and not jointly, from the Company, the Option
Shares at the Purchase Price less an amount per share equal to any dividends or distributions
declared by the Company and payable on the Underwritten Shares but not payable on the Option
Shares. If any Option Shares are to be purchased, the number of Option Shares to be purchased by
each Underwriter shall be the number of Option Shares which bears the same ratio to the aggregate
number of Option Shares being purchased as the number of Underwritten Shares set forth opposite the
name of such Underwriter in Schedule I hereto (or such number increased as set forth in Section 10
hereof) bears to the aggregate number of Underwritten Shares being purchased from the Company by
the several Underwriters, subject, however, to such adjustments to eliminate any fractional Shares
as the Representatives in their sole discretion shall make.
The Underwriters may exercise the option to purchase Option Shares at any time in whole, or
from time to time in part, on or before the thirtieth day following the date of the Prospectus, by
written notice from the Representatives to the Company. Such notice shall set forth the aggregate
number of Option Shares as to which the option is being exercised and the
2
date and time when the Option Shares are to be delivered and paid for, which may be the same
date and time as the Closing Date (as hereinafter defined) but shall not be earlier than the
Closing Date or later than the tenth full business day (as hereinafter defined) after the date of
such notice (unless such time and date are postponed in accordance with the provisions of Section
10 hereof). Any such notice shall be given at least one business day prior to the date and time of
delivery specified therein.
(b) The Company understands that the Underwriters intend to make a public offering of the
Shares as soon after the effectiveness of this Agreement as in the judgment of the Representatives
is advisable, and initially to offer the Shares on the terms set forth in the Prospectus. The
Company acknowledges and agrees that the Underwriters may offer and sell Shares to or through any
affiliate of an Underwriter.
(c) Payment for the Shares shall be made by wire transfer in immediately available funds to
the accounts specified by the Company to the Representatives, in the case of the Underwritten
Shares, at the offices of Xxxxxx Xxxxxxxx Xxxxx & Xxxxxxxx LLP at [10:00 A.M.], New York City time,
on [ ], 2011, or at such other time or place on the same or such other date, not later
than the fifth business day thereafter, as the Representatives and the Company may agree upon in
writing or, in the case of the Option Shares, on the date and at the time and place specified by
the Representatives in the written notice of the Underwriters’ election to purchase such Option
Shares. The time and date of such payment for the Underwritten Shares is referred to herein as the
“Closing Date,” and the time and date for such payment for the Option Shares, if other than the
Closing Date, is herein referred to as the “Additional Closing Date.”
Payment for the Shares to be purchased on the Closing Date or the Additional Closing Date, as
the case may be, shall be made against delivery to the Representatives for the respective accounts
of the several Underwriters of the Shares to be purchased on such date, with any transfer taxes
payable in connection with the sale of such Shares duly paid by the Company. Delivery of the
Shares shall be made through the facilities of The Depository Trust Company (“DTC”) unless the
Representatives shall otherwise instruct. Instructions to the transfer agent for delivery of the
Shares will be made available for inspection by the Representatives not later than 1:00 P.M., New
York City time, on the business day prior to the Closing Date or the Additional Closing Date, as
the case may be.
(d) The Company acknowledges and agrees that the Underwriters are acting solely in the
capacity of an arm’s length contractual counterparty to the Company with respect to the offering of
Shares contemplated hereby (including in connection with determining the terms of the offering) and
not as a financial advisor or a fiduciary to, or an agent of, the Company or any other person.
Additionally, neither the Representatives nor any other Underwriter is advising the Company or any
other person as to any legal, tax, investment, accounting or regulatory matters in any
jurisdiction. The Company shall consult with its own advisors concerning such matters and shall be
responsible for making its own independent investigation and appraisal of the transactions
contemplated hereby, and the Underwriters shall have no responsibility or liability to the Company
with respect thereto. Any review by the Underwriters of the Company, the transactions contemplated
hereby or other matters relating to such transactions will be performed solely for the benefit of
the Underwriters and shall not be on behalf of the Company.
3
(e) It is understood that you, individually and not as Representatives of the several
Underwriters, may (but shall not be obligated to) make payment to the Company on behalf of any
Underwriter for the Shares to be purchased by such Underwriter. Any such payment by you shall not
relieve any such Underwriter of any of its obligations hereunder. Nothing herein contained shall
create with respect to any of the Underwriters an unincorporated association or partnership with
the Company.
3. Representations and Warranties of the Company. The Company represents and warrants
to each Underwriter that:
(a) Preliminary Prospectus. No order preventing or suspending the use of any
Preliminary Prospectus has been issued by the Commission, and each Preliminary Prospectus
included in the Pricing Disclosure Package, at the time of filing thereof, complied in all
material respects with the Securities Act, and no Preliminary Prospectus, at the time of
filing thereof, contained any untrue statement of a material fact or omitted to state a
material fact necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading; provided that the Company
makes no representation and warranty with respect to any statements or omissions made in
reliance upon and in conformity with information relating to any Underwriter furnished to
the Company in writing by such Underwriter through the Representatives expressly for use in
any Preliminary Prospectus, it being understood and agreed that the only such information
furnished by any Underwriter consists of the information described as such in Section 7(b)
hereof.
(b) Pricing Disclosure Package. The Pricing Disclosure Package as of the Applicable
Time did not, and as of the Closing Date and as of the Additional Closing Date, as the case
may be, will not, contain any untrue statement of a material fact or omit to state a
material fact necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading; provided that the Company
makes no representation and warranty with respect to any statements or omissions made in
reliance upon and in conformity with information relating to any Underwriter furnished to
the Company in writing by such Underwriter through the Representatives expressly for use in
such Pricing Disclosure Package, it being understood and agreed that the only such
information furnished by any Underwriter consists of the information described as such in
Section 7(b) hereof.
(c) Issuer Free Writing Prospectus. Other than the Registration Statement, the
Preliminary Prospectus and the Prospectus, the Company (including its agents and
representatives, other than the Underwriters in their capacity as such) has not prepared,
used, authorized, approved or referred to and will not prepare, use, authorize, approve or
refer to any “written communication” (as defined in Rule 405 under the Securities Act) that
constitutes an offer to sell or solicitation of an offer to buy the Shares (each such
communication by the Company or its agents and representatives (other than a communication
referred to in clause (i) below) an “Issuer Free Writing Prospectus”) other than (i) any
document not constituting a prospectus pursuant to Section 2(a)(10)(a) of the Securities Act
or Rule 134 under the Securities Act or (ii) the documents listed on Annex B hereto, each
electronic road show and any other written communications approved in
4
writing in advance by the Representatives. Each such Issuer Free Writing Prospectus
complied in all material respects with the Securities Act, has been or will be (within the
time period specified in Rule 433) filed in accordance with the Securities Act (to the
extent required thereby) and, when taken together with the Pricing Disclosure Package
accompanying, or delivered prior to delivery of, such Issuer Free Writing Prospectus, did
not, as of the Applicable Time, contain any untrue statement of a material fact or omit to
state a material fact necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading; provided that the Company
makes no representation and warranty with respect to any statements or omissions made in
each such Issuer Free Writing Prospectus in reliance upon and in conformity with information
relating to any Underwriter furnished to the Company in writing by such Underwriter through
the Representatives expressly for use in such Issuer Free Writing Prospectus, it being
understood and agreed that the only such information furnished by any Underwriter consists
of the information described as such in Section 7(b) hereof.
(d) Registration Statement and Prospectus. The Registration Statement has been
declared effective by the Commission. No order suspending the effectiveness of the
Registration Statement has been issued by the Commission, and no proceeding for that purpose
or pursuant to Section 8A of the Securities Act against the Company or related to the
offering of the Shares has been initiated or threatened by the Commission; as of the
applicable effective date of the Registration Statement and any post-effective amendment
thereto, the Registration Statement and any such post-effective amendment complied and will
comply in all material respects with the Securities Act, and did not and will not contain
any untrue statement of a material fact or omit to state a material fact required to be
stated therein or necessary in order to make the statements therein not misleading; and as
of the date of the Prospectus and any amendment or supplement thereto and as of the Closing
Date and as of the Additional Closing Date, as the case may be, the Prospectus will not
contain any untrue statement of a material fact or omit to state a material fact necessary
in order to make the statements therein, in the light of the circumstances under which they
were made, not misleading; provided that the Company makes no representation and
warranty with respect to any statements or omissions made in reliance upon and in conformity
with information furnished to the Company in writing by any Underwriter through the
Representatives expressly for use in the Registration Statement and the Prospectus and any
amendment or supplement thereto, it being understood and agreed that the only such
information furnished by any Underwriter consists of the information described as such in
Section 7(b) hereof.
(e) Financial Statements. The financial statements (including the related notes
thereto) of the Company and its consolidated subsidiaries included in the Registration
Statement, the Pricing Disclosure Package and the Prospectus comply in all material respects
with the applicable requirements of the Securities Act and present fairly the financial
position of the Company and its consolidated subsidiaries as of the dates indicated and the
results of their operations and the changes in their cash flows for the periods specified;
such financial statements have been prepared in conformity with generally accepted
accounting principles in the United States applied on a consistent basis throughout the
periods covered thereby, except that the unaudited financial statements are subject to
normal year-end adjustments and do not contain certain
5
footnotes as permitted by the applicable rules of the Commission; any supporting
schedules included in the Registration Statement present fairly the information required to
be stated therein; and the other financial information included in the Registration
Statement, the Pricing Disclosure Package and the Prospectus has been derived from the
accounting records of the Company and its consolidated subsidiaries and presents fairly the
information shown thereby; and except as disclosed in the Registration Statement, the
Pricing Disclosure Package and the Prospectus, there are no material off-balance sheet
arrangements (as defined in Regulation S-K under the Securities Act (“Regulation S-K”), Item
303(a)(4)(ii)) or any other relationships with unconsolidated entities or other persons,
that may have a material current or, to the Company’s knowledge, material future effect on
the Company’s financial condition, results of operations, liquidity, capital expenditures,
capital resources or significant components of revenue or expenses. All disclosures
contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus
regarding “non-GAAP financial measures” comply with Regulation G of the Exchange Act (as
defined in Rule 101 thereunder) and Item 10 of Regulation S-K, to the extent applicable.
(f) No Material Adverse Change. Since the date of the most recent financial statements
of the Company included in the Registration Statement, the Pricing Disclosure Package and
the Prospectus, (i) there has not been any change in the capital stock (other than the
issuance of shares of Common Stock upon exercise of stock options and warrants described as
outstanding in, and the grant of options and awards under existing equity incentive plans
described in, the Registration Statement, the Pricing Disclosure Package and the
Prospectus), short-term debt or long-term debt of the Company or any of its subsidiaries
(other than borrowings and repayments in the ordinary course of business under such credit
facilities as are described in the Registrations Statement, the Pricing Disclosure Package
and the Prospectus), or any dividend or distribution of any kind declared, set aside for
payment, paid or made by the Company on any class of capital stock, or any material adverse
change, or any development involving a prospective material adverse change, in or affecting
the business, properties, management, financial position, stockholders’ equity, results of
operations or prospects of the Company and its subsidiaries taken as a whole; (ii) neither
the Company nor any of its subsidiaries has entered into any transaction or agreement
(whether or not in the ordinary course of business) that is material to the Company and its
subsidiaries taken as a whole or incurred any liability or obligation, direct or contingent,
that is material to the Company and its subsidiaries taken as a whole; and (iii) neither the
Company nor any of its subsidiaries has sustained any loss or interference with its business
that is material to the Company and its subsidiaries taken as a whole and that is either
from fire, explosion, flood or other calamity, whether or not covered by insurance, or from
any labor disturbance or dispute or any action, order or decree of any court or arbitrator
or governmental or regulatory authority; except in each case as otherwise disclosed in the
Registration Statement, the Pricing Disclosure Package and the Prospectus.
(g) Organization and Good Standing. The Company and each of its subsidiaries have been
duly organized and are validly existing and in good standing under the laws of their
respective jurisdictions of organization, are duly qualified to do business and are in good
standing in each jurisdiction in which their respective ownership or lease of property or
the conduct of their respective businesses requires such qualification, and
6
have all power and authority necessary to own or hold their respective properties and
to conduct the businesses in which they are engaged, except where the failure to be so
qualified or in good standing or have such power or authority would not, individually or in
the aggregate, have a material adverse effect on the earnings, business, properties,
management, operations, condition (financial or otherwise), results of operations or
prospects of the Company and its subsidiaries taken as a whole or on the performance by the
Company of its obligations under this Agreement (a “Material Adverse Effect”). The Company
does not own or control, directly or indirectly, any corporation, association or other
entity other than the subsidiaries listed in Exhibit 21 to the Registration Statement.
(h) Capitalization. The Company has an authorized capitalization as set forth in the
Registration Statement, the Pricing Disclosure Package and the Prospectus under the heading
“Capitalization”; all the outstanding shares of capital stock of the Company have been duly
and validly authorized and issued and are fully paid and non-assessable and are not subject
to any pre-emptive or similar rights that have not been waived or otherwise complied with;
and as of the Closing Date or Additional Closing Date, as the case may be, all of the
outstanding shares of capital stock of the Company will be duly and validly authorized and
issued and will be fully paid and non-assessable and will not be subject to any pre-emptive
or similar rights that will not have been waived or otherwise complied with; except as
described in or expressly contemplated by the Pricing Disclosure Package and the Prospectus,
there are no outstanding rights (including, without limitation, pre-emptive rights),
warrants or options to acquire, or instruments convertible into or exchangeable for, any
shares of capital stock or other equity interest in the Company or any of its subsidiaries,
or any contract, commitment, agreement, understanding or arrangement of any kind relating to
the issuance of any capital stock of the Company or any such subsidiary, any such
convertible or exchangeable securities or any such rights, warrants or options; the capital
stock of the Company conforms in all material respects to the description thereof contained
in the Registration Statement, the Pricing Disclosure Package and the Prospectus; and all
the outstanding shares of capital stock or other equity interests of each subsidiary owned,
directly or indirectly, by the Company have been duly and validly authorized and issued, are
fully paid and non-assessable and are owned directly or indirectly by the Company, free and
clear of any lien, charge, encumbrance, security interest, restriction on voting or transfer
or any other claim of any third party. The form of certificates for the Shares conforms to
the corporate law of the jurisdiction of the Company’s incorporation and to any requirements
of the Company’s organizational documents. Subsequent to the respective dates as of which
information is given in the Registration Statement, the Pricing Disclosure Package and the
Prospectus, except as otherwise specifically stated therein or in this Agreement, the
Company has not: (i) issued any securities or incurred any liability or obligation, direct
or contingent, for borrowed money (other than borrowings in the ordinary course of business
under such credit facilities as are described in the Registrations Statement, the Pricing
Disclosure Package and the Prospectus); or (ii) declared or paid any dividend or made any
other distribution on or in respect to its capital stock.
(i) Stock Options. With respect to the stock options (the “Stock Options”) granted
pursuant to the stock-based compensation plans of the Company and its subsidiaries (the
“Company Stock Plans”), (i) each Stock Option intended to qualify as an
7
“incentive stock option” under Section 422 of the Code so qualifies, (ii) each
non-qualified Stock Option was issued in accordance with the rules for an exemption under
Rule 409A of the Code, (iii) each grant of a Stock Option was duly authorized by all
necessary corporate action, including, as applicable, approval by the board of directors of
the Company (or a duly constituted and authorized committee thereof) and any required
stockholder approval by the necessary number of votes or written consents, and the award
agreement governing such grant (if any) was duly executed and delivered by each party
thereto, (iv) each such grant was made in accordance with the terms of the Company Stock
Plans and all other applicable laws and regulatory rules or requirements, and (v) each such
grant was properly accounted for in accordance with GAAP in the financial statements
(including the related notes) of the Company.
(j) Due Authorization. The Company has the requisite corporate power and authority to
execute and deliver this Agreement and to perform its obligations hereunder; and all action
required to be taken for the due and proper authorization, execution and delivery by it of
this Agreement and the consummation by it of the transactions contemplated hereby has been
duly and validly taken.
(k) Underwriting Agreement. This Agreement has been duly authorized, executed and
delivered by the Company.
(l) The Shares. The Shares to be issued and sold by the Company hereunder have been
duly authorized by the Company and, when issued and delivered and paid for as provided
herein, will be duly and validly issued, will be fully paid and nonassessable and will
conform to the descriptions thereof in the Registration Statement, the Pricing Disclosure
Package and the Prospectus; and the issuance of the Shares is not subject to any preemptive
or similar rights which have not been waived or otherwise complied with.
(m) No Violation or Default. Neither the Company nor any of its subsidiaries is (i) in
violation of its charter or by-laws or similar organizational documents; (ii) in default,
and no event has occurred that, with notice or lapse of time or both, would constitute such
a default, in the due performance or observance of any term, covenant or condition contained
in any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument
to which the Company or any of its subsidiaries is a party or by which the Company or any of
its subsidiaries is bound or to which any of the property or assets of the Company or any of
its subsidiaries is subject; or (iii) in violation of any law or statute or any judgment,
order, rule or regulation of any court or arbitrator or governmental or regulatory
authority, except, in the case of clauses (ii) and (iii) above, for any such default or
violation that would not, individually or in the aggregate, have a Material Adverse Effect.
(n) No Conflicts. The execution, delivery and performance by the Company of this
Agreement, the issuance and sale of the Underwritten Shares by the Company and the
consummation by the Company of the transactions contemplated by this Agreement will not (i)
conflict with or result in a breach or violation of any of the terms or provisions of, or
constitute a default under, or result in the creation or imposition of any lien, charge or
encumbrance upon any property or assets of the Company or any of its subsidiaries
8
pursuant to, any indenture, mortgage, deed of trust, loan agreement or other agreement
or instrument to which the Company or any of its subsidiaries is a party or by which the
Company or any of its subsidiaries is bound or to which any of the property or assets of the
Company or any of its subsidiaries is subject, (ii) result in any violation of the
provisions of the charter or by-laws or similar organizational documents of the Company or
any of its subsidiaries or (iii) result in the violation of any law or statute or any
judgment, order, rule or regulation of any court or arbitrator or governmental or
regulatory authority, except, in the case of clauses (i) and (iii) above, for any such
conflict, breach, violation or default that, individually or in the aggregate, would not (x)
reasonably be expected to have a Material Adverse Effect or (y) adversely affect the
enforceability of this Agreement against the Company or the ability of the Company to
perform its obligations under, or consummate the transactions contemplated by, this
Agreement or (z) impose any liability for tortious interference on any of the Underwriters.
(o) No Consents Required. No consent, approval, authorization, order, license,
registration or qualification of or with any court or arbitrator or governmental or
regulatory authority is required for the execution, delivery and performance by the Company
of this Agreement, the issuance and sale of the Shares and the consummation of the
transactions contemplated by this Agreement, except (i) the registration of the Shares under
the Securities Act, (ii) such consents, approvals, authorizations, orders and registrations
or qualifications as may be required by the Financial Industry Regulatory Authority, Inc.
(“FINRA”) and under applicable state securities laws in connection with the purchase and
distribution of the Shares by the Underwriters and (iii) such consents, approvals,
authorizations, orders and registrations or qualifications as may be required by the Nasdaq
Stock Market and which have been obtained.
(p) Legal Proceedings. Except as described in the Registration Statement, the Pricing
Disclosure Package and the Prospectus, there are no legal, governmental or regulatory
investigations, actions, suits or proceedings pending to which the Company or any of its
subsidiaries is or may be a party or to which any property of the Company or any of its
subsidiaries is or may be the subject that, individually or in the aggregate, if determined
adversely to the Company or any of its subsidiaries, could reasonably be expected to have a
Material Adverse Effect; no such investigations, actions, suits or proceedings are
threatened or, to the knowledge of the Company, contemplated by any governmental or
regulatory authority or threatened by others; and (i) there are no current or pending legal,
governmental or regulatory actions, suits or proceedings that are required under the
Securities Act to be described in the Registration Statement, the Pricing Disclosure Package
or the Prospectus that are not so described in the Registration Statement, the Pricing
Disclosure Package and the Prospectus and (ii) there are no statutes, regulations or
contracts or other documents that are required under the Securities Act to be filed as
exhibits to the Registration Statement or described in the Registration Statement, the
Pricing Disclosure Package or the Prospectus that are not so filed as exhibits to the
Registration Statement or described in the Registration Statement, the Pricing Disclosure
Package and the Prospectus.
9
(q) Independent Accountants. Deloitte & Touche LLP, which has certified certain
financial statements of the Company and its subsidiaries, is an independent registered
public accounting firm with respect to the Company and its subsidiaries within the
applicable rules and regulations adopted by the Commission and the Public Company Accounting
Oversight Board (United States) and as required by the Securities Act.
(r) Title to Real and Personal Property. The Company and its subsidiaries have good
and marketable title in fee simple (in the case of real property) to, or have valid and
marketable rights to lease or otherwise use, all items of real and personal property and
assets that are material to the respective businesses of the Company and its subsidiaries,
in each case free and clear of all liens, encumbrances, claims and defects and imperfections
of title except those that (i) do not materially interfere with the use made and proposed to
be made of such property by the Company and its subsidiaries, (ii) are otherwise described
in or contemplated by the Registration Statement, the Pricing Disclosure Package and the
Prospectus, or (iii) would not, individually or in the aggregate, have a Material Adverse
Effect.
(s) Title to Intellectual Property. Except as would not, individually or in the
aggregate, have a Material Adverse Effect, the Company and its subsidiaries own or possess
valid rights to use all intellectual property rights, including, without limitation,
patents, patent licenses, trademarks, trademark licenses, service marks, trade names,
copyrights, copyright licenses, works of authorship, all applications and registrations for
the foregoing, know-how (including trade secrets and other unpatented and/or unpatentable
proprietary or confidential information, systems or procedures) and all other similar rights
(collectively, the “Intellectual Property”) necessary for the conduct of their respective
businesses as currently conducted and as proposed to be conducted (as described in the
Registration Statement, the Pricing Disclosure Package and the Prospectus), and no third
party is known by the Company to be violating or infringing the Intellectual Property rights
of the Company or its subsidiaries. The conduct of the Company and its subsidiaries’
respective businesses will not infringe, violate or conflict with any such rights of others,
except as would not, individually or in the aggregate, have a Material Adverse Effect. The
Company and its subsidiaries have not received any notice of any claim of infringement,
misappropriation or conflict with any such rights of others in connection with its
Intellectual Property, which could reasonably be expected to result in a Material Adverse
Effect.
(t) No Undisclosed Relationships. No relationship, direct or indirect, exists between
or among the Company or any of its subsidiaries, on the one hand, and the directors,
officers, stockholders, customers or suppliers of the Company or any of its subsidiaries, on
the other, that is required by the Securities Act to be described in the Registration
Statement and the Prospectus and that is not so described in such documents and in the
Pricing Disclosure Package.
(u) Investment Company Act. The Company is not and, after giving effect to the
offering and sale of the Shares and the application of the proceeds thereof received by the
Company as described in the Registration Statement, the Pricing Disclosure Package and the
Prospectus, will not be required to register as an “investment company” or an
10
entity “controlled” by an “investment company” within the meaning of the Investment
Company Act of 1940, as amended, and the rules and regulations of the Commission thereunder
(collectively, the “Investment Company Act”).
(v) Taxes. Except as otherwise disclosed in the Registration Statement, the Pricing
Disclosure Package and the Prospectus, (i) the Company and its subsidiaries have paid all
federal, state, local and foreign taxes and filed all tax returns required to be paid or
filed through the date hereof, except with respect to taxes and tax returns contested in
good faith and except where the failure to so pay or file would not, individually or in the
aggregate, have a Material Adverse Effect; and (ii) there is no tax deficiency that has
been, or could reasonably be expected to be, asserted against the Company or any of its
subsidiaries or any of their respective properties or assets, except where such tax
deficiency would not, individually or in the aggregate, have a Material Adverse Effect.
(w) Licenses and Permits. The Company and its subsidiaries possess all licenses,
certificates, permits and other authorizations issued by, and have made all declarations and
filings with, the appropriate federal, state, local or foreign governmental or regulatory
authorities that are necessary for the ownership or lease of their respective properties or
the conduct of their respective businesses as described in the Registration Statement, the
Pricing Disclosure Package and the Prospectus, except where the failure to possess or make
the same would not, individually or in the aggregate, have a Material Adverse Effect; and
except as described in the Registration Statement, the Pricing Disclosure Package and the
Prospectus, neither the Company nor any of its subsidiaries has received notice of any
revocation or modification of any such license, certificate, permit or authorization or has
any reason to believe that any such license, certificate, permit or authorization will not
be renewed in the ordinary course.
(x) No Labor Disputes. No labor disturbance by or dispute with employees of the
Company or any of its subsidiaries exists or, to the knowledge of the Company, is
threatened, and the Company is not aware of any existing or imminent labor disturbance by,
or dispute with, the employees of any of its or its subsidiaries’ principal suppliers,
contractors or customers, except as would not, individually or in the aggregate, have a
Material Adverse Effect.
(y) Occupational Laws. The Company and each of its subsidiaries (A) is in compliance,
in all material respects, with any and all applicable foreign, federal, state and local
laws, rules, regulations, treaties, statutes and codes promulgated by any and all
governmental authorities (including pursuant to the Occupational Health and Safety Act)
relating to the protection of human health and safety in the workplace (“Occupational
Laws”); (B) has received all material permits, licenses or other approvals required of it
under applicable Occupational Laws to conduct its business as currently conducted; and (C)
is in compliance, in all material respects, with all terms and conditions of such permit,
license or approval. No action, proceeding, revocation proceeding, writ, injunction or
claim is pending or, to the Company’s knowledge, threatened against the Company or any of
its subsidiaries relating to Occupational Laws, and the Company does not have knowledge of
any facts, circumstances or developments relating to its operations
11
or cost accounting practices that could reasonably be expected to form the basis for or
give rise to such actions, suits, investigations or proceedings.
(z) Compliance with and Liability under Environmental Laws. (i) The Company and its
subsidiaries (a) are, and at all prior times were, in compliance with any and all applicable
federal, state, local and foreign laws, rules, regulations, requirements, decisions,
judgments, decrees, orders and the common law relating to pollution or the protection of the
environment, natural resources or human health or safety, including those relating to the
generation, storage, treatment, use, handling, transportation, Release or threat of Release
of Hazardous Materials (collectively, “Environmental Laws”), (b) have received and are in
compliance with all permits, licenses, certificates or other authorizations or approvals
required of them under applicable Environmental Laws to conduct their respective businesses,
(c) have not received notice of any actual or potential liability under or relating to, or
actual or potential violation of, any Environmental Laws, including for the investigation or
remediation of any Release or threat of Release of Hazardous Materials, and have no
knowledge of any event or condition that would reasonably be expected to result in any such
notice, (d) are not conducting or paying for, in whole or in part, any investigation,
remediation or other corrective action pursuant to any Environmental Law at any location,
and (e) are not a party to any order, decree or agreement that imposes any obligation or
liability under any Environmental Law, and (ii) there are no costs or liabilities associated
with Environmental Laws of or relating to the Company or its subsidiaries, except in the
case of each of (i) and (ii) above, for any such matter, as would not, individually or in
the aggregate, reasonably be expected to have a Material Adverse Effect; and (iii) except as
described in the Registration Statement, the Pricing Disclosure Package and the Prospectus,
(a) there are no proceedings that are pending, or that are known by the Company to be
threatened, against the Company or any of its subsidiaries under any Environmental Laws in
which a governmental entity is also a party, other than such proceedings regarding which it
is reasonably believed no monetary sanctions of $100,000 or more will be imposed, (b) the
Company and its subsidiaries are not aware of any facts or issues regarding compliance with
Environmental Laws, or liabilities or other obligations under Environmental Laws, including
the Release or threat of Release of Hazardous Materials, that would reasonably be expected
to have a Material Adverse Effect, and (c) none of the Company and its subsidiaries
anticipates material capital expenditures relating to any Environmental Laws.
(aa) Hazardous Materials. There has been no storage, generation, transportation, use,
handling, treatment, Release or threat of Release of Hazardous Materials by, relating to or
caused by the Company or any of its subsidiaries (or, to the knowledge of the Company and
its subsidiaries, any other entity (including any predecessor) for whose acts or omissions
the Company or any of its subsidiaries is or could reasonably be expected to be liable) at,
on, under or from any property or facility now or previously owned, operated or leased by
the Company or any of its subsidiaries, or at, on, under or from any other property or
facility, in violation of any Environmental Laws or in a manner or amount or to a location
that could reasonably be expected to result in any liability under any Environmental Law,
except for any violation or liability which would not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect. “Hazardous Materials” means any
material, chemical,
12
substance, waste, pollutant, contaminant, compound, mixture, or constituent thereof, in
any form or amount, including petroleum (including crude oil or any fraction thereof) and
petroleum products, natural gas liquids, asbestos and asbestos containing materials,
naturally occurring radioactive materials, brine, and drilling mud, regulated or which can
give rise to liability under any Environmental Law. “Release” means any spilling, leaking,
seepage, pumping, pouring, emitting, emptying, discharging, injecting, escaping, leaching,
dumping, disposing, depositing, dispersing, or migrating in, into or through the
environment, or in, into, from or through any building or structure.
(bb) Compliance with ERISA. (i) Each employee benefit plan, within the meaning of
Section 3(3) of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”),
for which the Company or any member of its “Controlled Group” (defined as any organization
which is a member of a controlled group of organizations within the meaning of Section 414
of the Internal Revenue Code of 1986, as amended (the “Code”)) would have any liability
(each, a “Plan”) has been established and maintained in compliance with its terms and the
requirements of any applicable statutes, orders, rules and regulations, including but not
limited to, ERISA and the Code, except for noncompliance that could not reasonably be
expected to result in material liability to the Company or its subsidiaries; (ii) no
prohibited transaction, within the meaning of Section 406 of ERISA or Section 4975 of the
Code, has occurred with respect to any Plan excluding transactions effected pursuant to a
statutory or administrative exemption that could reasonably be expected to result in a
material liability to the Company or its subsidiaries; (iii) for each Plan that is subject
to the funding rules of Section 412 of the Code or Section 302 of ERISA, the minimum funding
standard of Section 412 of the Code or Section 302 of ERISA, as applicable, has been
satisfied (without taking into account any waiver thereof or extension of any amortization
period) and is reasonably expected to be satisfied in the future (without taking into
account any waiver thereof or extension of any amortization period); (iv) the fair market
value of the assets of each Plan exceeds the present value of all benefits accrued under
such Plan (determined based on those assumptions used to fund such Plan); (v) no “reportable
event” (within the meaning of Section 4043(c) of ERISA) has occurred or is reasonably
expected to occur that either has resulted, or could reasonably be expected to result, in
material liability to the Company or its subsidiaries; (vi) neither the Company nor any
member of the Controlled Group has incurred, nor reasonably expects to incur, any liability
under Title IV of ERISA (other than contributions to the Plan or premiums to the PBGC, in
the ordinary course and without default) in respect of a Plan (including a “multiemployer
plan”, within the meaning of Section 4001(a)(3) of ERISA); and (vii) there is no pending
audit or investigation by the Internal Revenue Service, the U.S. Department of Labor, the
Pension Benefit Guaranty Corporation or any other governmental agency or any foreign
regulatory agency with respect to any Plan that could reasonably be expected to result in
material liability to the Company or its subsidiaries. None of the following events has
occurred or is reasonably likely to occur: (x) a material increase in the aggregate amount
of contributions required to be made to all Plans by the Company or its subsidiaries in the
current fiscal year of the Company and its subsidiaries compared to the amount of such
contributions made in the Company and its subsidiaries’ most recently completed fiscal year;
or (y) a material increase in the Company and its subsidiaries’ “accumulated post-retirement
benefit obligations” (within the meaning of Statement of Financial Accounting
Standards 106) compared to the amount of such obligations in the Company and its
subsidiaries’ most recently completed fiscal year.
13
(cc) Disclosure Controls. The Company and its subsidiaries maintain an effective
system of “disclosure controls and procedures” (as defined in Rule 13a-15(e) of the Exchange
Act) that complies with the requirements of the Exchange Act and that has been designed to
ensure that information required to be disclosed by the Company in reports that it files or
submits under the Exchange Act is recorded, processed, summarized and reported within the
time periods specified in the Commission’s rules and forms, including controls and
procedures designed to ensure that such information is accumulated and communicated to the
Company’s management as appropriate to allow timely decisions regarding required disclosure.
(dd) Accounting Controls. The Company and its subsidiaries maintain systems of
“internal control over financial reporting” (as defined in Rule 13a-15(f) of the Exchange
Act) and have been designed by, or under the supervision of, their respective principal
executive and principal financial officers, or persons performing similar functions, to
provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with generally
accepted accounting principles, including, but not limited to, internal accounting controls
sufficient to provide reasonable assurance that (i) transactions are executed in accordance
with management’s general or specific authorizations; (ii) transactions are recorded as
necessary to permit preparation of financial statements in conformity with generally
accepted accounting principles and to maintain asset accountability; (iii) access to assets
is permitted only in accordance with management’s general or specific authorization; and
(iv) the recorded accountability for assets is compared with the existing assets at
reasonable intervals and appropriate action is taken with respect to any differences.
Except as disclosed in the Registration Statement, the Pricing Disclosure Package and the
Prospectus, the Company’s internal control over financial reporting is effective and none of
the Company, its board of directors and audit committee is aware of any “significant
deficiencies” or “material weaknesses” (each as defined by the Public Company Accounting
Oversight Board) in its internal control over financial reporting, or any fraud, whether or
not material, that involves management or other employees of the Company who have a
significant role in the Company’s internal controls. The Company’s auditors and the Audit
Committee of the Board of Directors of the Company have been advised of: (i) all significant
deficiencies and material weaknesses in the design or operation of internal controls over
financial reporting which have adversely affected or are reasonably likely to adversely
affect the Company’s ability to record, process, summarize and report financial information
(it being understood that, as of the date hereof, the Company is not required to comply with
Section 404 of the Xxxxxxxx-Xxxxx Act); and (ii) any fraud of which the Company has
knowledge, whether or not material, that involves management or other employees who have a
significant role in the Company’s internal controls over financial reporting.
(ee) Insurance. The Company and its subsidiaries have insurance covering their
respective properties, operations, personnel and businesses, including business interruption
insurance, which insurance is in amounts and insures against such losses and
14
risks as the Company reasonably believes are adequate to protect the Company and its
subsidiaries as a whole and their respective businesses; and neither the Company nor any of
its subsidiaries has (i) received notice from any insurer or agent of such insurer that
capital improvements or other expenditures are required or necessary to be made in order to
continue such insurance or (ii) any reason to believe that it will not be able to renew its
existing insurance coverage as and when such coverage expires or to obtain similar coverage
at reasonable cost from similar insurers as may be necessary to continue its business.
(ff) No Unlawful Payments. Neither the Company nor any of its subsidiaries nor, to the
knowledge of the Company, any director, officer, agent, employee or other person associated
with or acting on behalf of the Company or any of its subsidiaries has (i) used any
corporate funds for any unlawful contribution, gift, entertainment or other unlawful expense
relating to political activity; (ii) made any direct or indirect unlawful payment to any
foreign or domestic government official or employee from corporate funds; (iii) violated or
is in violation of any provision of the Foreign Corrupt Practices Act of 1977; or (iv) made
any bribe, unlawful rebate, payoff, influence payment, kickback or other unlawful payment.
(gg) Compliance with Anti-Money Laundering Laws. The operations of the Company and its
subsidiaries are and have been conducted at all times in compliance with applicable
financial recordkeeping and reporting requirements of the Currency and Foreign Transactions
Reporting Act of 1970, as amended by Title III of the United and Strengthening America by
Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001, and
the applicable anti-money laundering statutes of all jurisdictions where the Company and its
subsidiaries conduct business, the rules and regulations thereunder and any related or
similar rules, regulations or guidelines, issued, administered or enforced by any
governmental agency (collectively, the “Anti-Money Laundering Laws”) and no action, suit or
proceeding by or before any court or governmental agency, authority or body or any
arbitrator involving the Company or any of its subsidiaries with respect to the Anti-Money
Laundering Laws is pending or, to the knowledge of the Company, threatened.
(hh) Compliance with OFAC. None of the Company, any of its subsidiaries or, to the
knowledge of the Company, any director, officer, agent, employee or affiliate of the Company
or any of its subsidiaries is currently subject to any U.S. sanctions administered by the
Office of Foreign Assets Control of the U.S. Department of the Treasury (“OFAC”); and the
Company will not, directly or indirectly, use the proceeds of the offering of the
Underwritten Shares hereunder, or lend, contribute or otherwise make available such proceeds
to any subsidiary, joint venture partner or other person or entity, for the purpose of
financing the activities of any person currently subject to any U.S. sanctions administered
by OFAC.
(ii) Compliance with Customer Privacy Laws. The operations of the Company and its
subsidiaries are and have been conducted at all times in compliance with applicable privacy
and customer information requirements contained in any federal and state privacy laws and
regulations, including, without limitation, in Title V of the
15
Xxxxx-Xxxxx-Xxxxxx Act of 1999 and the applicable regulations promulgated thereunder,
except as would not reasonably be expected to have a Material Adverse Effect.
(jj) Compliance with Certain Consumer Protection Laws. The operations of the Company
and its subsidiaries are and have been conducted at all times in compliance with the
Truth-in-Lending Act (as amended by the Credit Card Accountability, Responsibility and
Disclosure Act), the Equal Credit Opportunity Act, the Fair Credit Reporting Act and the
Fair Debt Collection Practices Act, and the applicable regulations promulgated thereunder,
except as would not reasonably be expected to have a Material Adverse Effect.
(kk) No Restrictions on Subsidiaries. Except as described in the Registration
Statement, the Pricing Disclosure Package and the Prospectus, no subsidiary of the Company
is currently prohibited, directly or indirectly, under any agreement or other instrument to
which it is a party or is subject, from paying any dividends to the Company, from making any
other distribution on such subsidiary’s capital stock, from repaying to the Company any
loans or advances to such subsidiary from the Company or from transferring any of such
subsidiary’s properties or assets to the Company or any other subsidiary of the Company.
(ll) No Broker’s Fees. Neither the Company nor any of its subsidiaries is a party to
any contract, agreement or understanding with any person (other than this Agreement) that
would give rise to a valid claim against the Company or any of its subsidiaries or any
Underwriter for a brokerage commission, finder’s fee or like payment in connection with the
offering and sale of the Shares.
(mm) No Registration Rights. Except as described in the Registration Statement, the
Pricing Disclosure Package and the Prospectus, no person has the right to require the
Company or any of its subsidiaries to register any securities for sale under the Securities
Act by reason of the filing of the Registration Statement with the Commission or the
issuance and sale of the Shares by the Company hereunder.
(nn) No Stabilization. The Company has not taken, directly or indirectly, any action
designed to or that could reasonably be expected to cause or result in any stabilization or
manipulation of the price of the Shares. The Company acknowledges that the Underwriters may
engage in passive market making transactions in the Shares on the Nasdaq Market in
accordance with Regulation M under the Exchange Act.
(oo) Forward-Looking Statements. No forward-looking statement (within the meaning of
Section 27A of the Securities Act and Section 21E of the Exchange Act) contained in the
Registration Statement, the Pricing Disclosure Package or the Prospectus has been made or
reaffirmed without a reasonable basis or has been disclosed other than in good faith.
(pp) Statistical and Market Data. The statistical, industry-related and market-related
data included in the Registration Statement, Pricing Disclosure Package and the Prospectus
are based on or derived from sources which the Company reasonably and in
good faith believes are reliable and accurate in all material respects, and such data
agree with the sources from which they are derived.
00
(xx) Xxxxxxxx-Xxxxx Xxx. Solely to the extent that the Xxxxxxxx-Xxxxx Act of 2002, as
amended, and the rules and regulations promulgated by the Commission thereunder (the
“Xxxxxxxx-Xxxxx Act”) has been applicable to the Company, there is and has been no failure
on the part of the Company to comply in all material respects with any provision of the
Xxxxxxxx-Xxxxx Act. The Company has taken all necessary steps to ensure that it is in
compliance with all provisions of the Xxxxxxxx-Xxxxx Act that are in effect and with which
the Company is required to comply and is actively taking steps to ensure that it will be in
compliance with other provisions of the Xxxxxxxx-Xxxxx Act not currently in effect or which
will become applicable to the Company.
(rr) Status under the Securities Act. At the time of filing the Registration Statement
and any post-effective amendment thereto, at the earliest time thereafter that the Company
or any offering participant made a bona fide offer (within the meaning of Rule 164(h)(2)
under the Securities Act) of the Shares and at the date hereof, the Company was not and is
not an “ineligible issuer,” as defined in Rule 405 under the Securities Act. The Company
has paid the registration fee for this offering pursuant to Rule 456(b)(1) under the
Securities Act or will pay such fee within the time period required by such rule (without
giving effect to the proviso therein) and in any event prior to the Closing Date.
(ss) No FINRA Affiliation. Except as previously disclosed to counsel for the
Underwriters (including in FINRA questionnaires made available to such counsel) or as set
forth in the Registration Statement, Pricing Disclosure Package and the Prospectus, there
are no affiliations with members of the FINRA among the Company’s officers or directors or,
to the knowledge of the Company, any five percent or greater stockholders of the Company or
any beneficial owner of the Company’s unregistered equity securities that were acquired
during the 180-day period immediately preceding the initial filing date of the Registration
Statement.
Any certificate signed by any officer of the Company and delivered to you or to counsel for
the Underwriters shall be deemed a representation and warranty by the Company to each Underwriter
as to the matters covered thereby.
17
4. Further Agreements of the Company. The Company covenants and agrees with each
Underwriter that:
(a) Required Filings. The Company will file the final Prospectus with the Commission within
the time periods specified by Rule 424(b) and Rule 430A, 430B or 430C under the Securities Act,
will file any Issuer Free Writing Prospectus to the extent required by Rule 433 under the
Securities Act; and will furnish copies of the Prospectus and each Issuer Free Writing Prospectus
(to the extent not previously delivered) to the Underwriters in New York City prior to 10:00 A.M.,
New York City time, on the business day next succeeding the date of this Agreement in such
quantities as the Representatives may reasonably request. The Company will satisfy the conditions
in Rule 433 under the Securities Act to avoid a requirement to file with the Commission any
electronic road show. If the Company has elected to rely upon Rule 462(b) of the Securities Act to
increase the size of the offering registered under the Securities Act and the amended Registration
Statement filed pursuant to Rule 462(b) has not yet been filed and become effective, the Company
will prepare and file such amended Registration Statement with the Commission within the time
period required by, and otherwise in accordance with the provisions of, Rule 462(b) and the
Securities Act.
(b) Delivery of Copies. The Company will deliver, without charge, (i) to the Representatives,
two signed copies of the Registration Statement as originally filed and each amendment thereto, in
each case including all exhibits and consents filed therewith; and (ii) to each Underwriter, during
the Prospectus Delivery Period (as defined below), as many copies of the Prospectus (including all
amendments and supplements thereto and each Issuer Free Writing Prospectus) as the Representatives
may reasonably request. As used herein, the term “Prospectus Delivery Period” means such period of
time after the first date of the public offering of the Shares as in the opinion of counsel for the
Underwriters a prospectus relating to the Shares is required by law to be delivered (or required to
be delivered but for Rule 172 under the Securities Act) in connection with sales of the Shares by
any Underwriter or dealer.
(c) Amendments or Supplements, Issuer Free Writing Prospectuses. Before preparing, using,
authorizing, approving, referring to or filing any Issuer Free Writing Prospectus, and before
filing any amendment or supplement to the Registration Statement or the Prospectus, the Company
will furnish to the Representatives and counsel for the Underwriters a copy of the proposed Issuer
Free Writing Prospectus, amendment or supplement for review and will not prepare, use, authorize,
approve, refer to or file any such Issuer Free Writing Prospectus or file any such proposed
amendment or supplement to which the Representatives reasonably object.
(d) Notice to the Representatives. The Company will advise the Representatives promptly, and
confirm such advice in writing, (i) when the Registration Statement has become effective; (ii) when
any amendment to the Registration Statement has been filed or becomes effective; (iii) when any
supplement to the Prospectus or any Issuer Free Writing Prospectus or any amendment to the
Prospectus has been filed; (iv) of any request by the Commission for any amendment to the
Registration Statement or any amendment or supplement to the Prospectus or the receipt of any
comments from the Commission relating to the Registration Statement or any other request by the
Commission for any additional information; (v) of the issuance by the Commission of any order
suspending the effectiveness of the Registration Statement or
18
preventing or suspending the use of any Preliminary Prospectus, any of the Pricing Disclosure
Package or the Prospectus or the initiation or threatening of any proceeding for that purpose or
pursuant to Section 8A of the Securities Act; (vi) of the occurrence of any event within the
Prospectus Delivery Period as a result of which the Prospectus, the Pricing Disclosure Package or
any Issuer Free Writing Prospectus as then amended or supplemented would include any untrue
statement of a material fact or omit to state a material fact necessary in order to make the
statements therein, in the light of the circumstances existing when the Prospectus, the Pricing
Disclosure Package or any such Issuer Free Writing Prospectus is delivered to a purchaser, not
misleading; and (vii) of the receipt by the Company of any notice with respect to any suspension of
the qualification of the Shares for offer and sale in any jurisdiction or the initiation or
threatening of any proceeding for such purpose; and the Company will use its best efforts to
prevent the issuance of any such order suspending the effectiveness of the Registration Statement,
preventing or suspending the use of any Preliminary Prospectus, any of the Pricing Disclosure
Package or the Prospectus or suspending any such qualification of the Shares and, if any such order
is issued, will obtain as soon as possible the withdrawal thereof.
(e) Ongoing Compliance. (1) If during the Prospectus Delivery Period (i) any event shall
occur or condition shall exist as a result of which the Prospectus as then amended or supplemented
would include any untrue statement of a material fact or omit to state any material fact necessary
in order to make the statements therein, in the light of the circumstances existing when the
Prospectus is delivered to a purchaser, not misleading or (ii) it is necessary to amend or
supplement the Prospectus to comply with law, the Company will immediately notify the Underwriters
thereof and forthwith prepare and, subject to paragraph (c) above, file with the Commission and
furnish to the Underwriters and to such dealers as the Representatives may designate such
amendments or supplements to the Prospectus as may be necessary so that the statements in the
Prospectus as so amended or supplemented will not, in the light of the circumstances existing when
the Prospectus is delivered to a purchaser, be misleading or so that the Prospectus will comply
with law and (2) if at any time prior to the Closing Date (i) any event shall occur or condition
shall exist as a result of which the Pricing Disclosure Package as then amended or supplemented
would include any untrue statement of a material fact or omit to state any material fact necessary
in order to make the statements therein, in the light of the circumstances existing when the
Pricing Disclosure Package is delivered to a purchaser, not misleading or (ii) it is necessary to
amend or supplement the Pricing Disclosure Package to comply with law, the Company will immediately
notify the Underwriters thereof and forthwith prepare and, subject to paragraph (c) above, file
with the Commission (to the extent required) and furnish to the Underwriters and to such dealers as
the Representatives may designate, such amendments or supplements to the Pricing Disclosure Package
as may be necessary so that the statements in the Pricing Disclosure Package as so amended or
supplemented will not, in the light of the circumstances existing when the Pricing Disclosure
Package is delivered to a purchaser, be misleading or so that the Pricing Disclosure Package will
comply with law.
(f) Blue Sky Compliance. The Company will qualify the Shares for offer and sale under the
securities or Blue Sky laws of such jurisdictions as the Representatives shall reasonably request
and will continue such qualifications in effect so long as required for distribution of the Shares;
provided that the Company shall not be required to (i) qualify as a foreign corporation or
other entity or as a dealer in securities in any such jurisdiction where it would not otherwise be
required to so qualify, (ii) file any general consent to service of process
in any such jurisdiction or (iii) subject itself to taxation in any such jurisdiction if it is
not otherwise so subject.
19
(g) Earning Statement. The Company will make generally available to its security holders and
the Representatives as soon as practicable an earning statement that satisfies the provisions of
Section 11(a) of the Securities Act and Rule 158 of the Commission promulgated thereunder covering
a period of at least twelve months beginning with the first fiscal quarter of the Company occurring
after the “effective date” (as defined in Rule 158) of the Registration Statement.
(h) Clear Market. For a period of 180 days after the date of the Prospectus, the Company will
not (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase
any option or contract to sell, grant any option, right or warrant to purchase, or otherwise
transfer or dispose of, directly or indirectly, or file with the Commission a registration
statement under the Securities Act relating to, any shares of Common Stock or any securities
convertible into or exercisable or exchangeable for Common Stock, or publicly disclose the
intention to make any offer, sale, pledge, disposition or filing, or (ii) enter into any swap or
other agreement that transfers, in whole or in part, any of the economic consequences of ownership
of the Common Stock or any such other securities, whether any such transaction described in clause
(i) or (ii) above is to be settled by delivery of Common Stock or such other securities, in cash or
otherwise, without the prior written consent of Xxxxx Xxxxxxx & Co., other than: (A) the Shares to
be sold hereunder; (B) grants of options, shares of Common Stock and other awards to purchase or
receive shares of Common Stock under the Company Stock Plans that are in effect as of or prior to
the date hereof and are described in the Registration Statement, the Pricing Disclosure Package and
the Prospectus, or issuances of shares of Common Stock upon the exercise of options or other awards
granted under such Company Stock Plans; (C) the registration under the Securities Act of any
securities referenced in clause (B), any other filing by the Company of any registration statement
on Form S-8 (or any successor form) or the filing by the Company of any registration statement to
the extent that the registration statement is required pursuant to a registration rights agreement
in effect on the date hereof and disclosed in the Registration Statement, the Pricing Disclosure
Package and the Prospectus; (D) issuances of capital stock upon exercise of any options or warrants
or the conversion of shares of Preferred Stock in each case that are outstanding on the date of
this Agreement or permitted to be issued pursuant to this Section 4(h); and (E) issuances of Common
Stock in satisfaction of accrued dividends on the Preferred Stock outstanding on the date hereof
that become due upon the conversion of such Preferred Stock. Notwithstanding the foregoing, if (1)
during the last 17 days of the 180-day restricted period, the Company issues an earnings release or
material news or a material event relating to the Company occurs; or (2) prior to the expiration of
the 180-day restricted period, the Company announces that it will release earnings results during
the 16-day period beginning on the last day of the 180-day period, the restrictions imposed by this
Agreement shall continue to apply until the expiration of the 18-day period beginning on the
issuance of the earnings release or the occurrence of the material news or material event.
(i) Use of Proceeds. The Company will apply the net proceeds from the sale of the
Underwritten Shares as described in the Registration Statement, the Pricing Disclosure Package and
the Prospectus under the heading “Use of Proceeds”.
20
(j) No Stabilization. The Company will not take, directly or indirectly, any action designed
to or that could reasonably be expected to cause or result in any stabilization or manipulation of
the price of the Common Stock.
(k) Exchange Listing. The Company will use its best efforts to list for quotation the Shares
on the Nasdaq Global Select Market.
(l) Reports. During a period of one year from the date hereof, the Company will furnish to the
Representatives, as soon as they are available, copies of all reports or other communications
(financial or other) furnished to holders of the Shares, and copies of any reports and financial
statements furnished to or filed with the Commission or any national securities exchange or
automatic quotation system; provided the Company will be deemed to have furnished such
reports and financial statements to the Representatives to the extent they are filed on the
Commission’s Electronic Data Gathering, Analysis, and Retrieval system (or any successor system).
(m) Record Retention. The Company will, pursuant to reasonable procedures developed in good
faith, retain copies of each Issuer Free Writing Prospectus that is not filed with the Commission
in accordance with Rule 433 under the Securities Act.
(n) Xxxxxxxx-Xxxxx Compliance. The Company and its subsidiaries will comply in all material
respects with all applicable provisions of the Xxxxxxxx-Xxxxx Act.
(o) Filings. The Company will file with the Commission such reports as may be required by
Rule 463 under the Securities Act.
(p) Announcement of Lock-Up Release or Waivers. If Xxxxx Xxxxxxx & Co., in its sole
discretion, agrees to release or waive the restrictions of any Lock-Up Agreements entered into as
contemplated by Section 6(m) hereof between an officer or director of the Company and Xxxxx Xxxxxxx
& Co., and Xxxxx Xxxxxxx & Co. provides the Company with notice of the impending release or waiver
at least three business days before the effective date of such release or waiver, the Company
agrees to announce the impending release or waiver by a press release substantially in the form of
Annex E hereto through a major news service at least two business days before the effective date of
such release or waiver.
5. Certain Agreements of the Underwriters. Each Underwriter hereby represents and
agrees that:
(a) It has not used, authorized use of, referred to or participated in the planning for use
of, and will not use, authorize use of, refer to or participate in the planning for use of, any
“free writing prospectus”, as defined in Rule 405 under the Securities Act (which term includes use
of any written information furnished to the Commission by the Company and not incorporated by
reference into the Registration Statement and any press release issued by the Company) other than
(i) a free writing prospectus that contains no “issuer information” (as defined in Rule 433(h)(2)
under the Securities Act) that was not included in the Preliminary Prospectus or a previously filed
Issuer Free Writing Prospectus, (ii) any Issuer Free Writing Prospectus listed on Annex B or
prepared pursuant to Section 3(c) above (including any electronic road show), or (iii) any free
writing prospectus prepared by such underwriter and
21
approved by the Company in advance in writing (each such free writing prospectus referred to
in clauses (i) or (iii), an “Underwriter Free Writing Prospectus”).
(b) It has not and will not, without the prior written consent of the Company, use any free
writing prospectus that contains the final terms of the Shares unless such terms have previously
been included in a free writing prospectus filed with the Commission; provided that
Underwriters may use a term sheet substantially in the form of Annex C hereto without the consent
of the Company; provided further that any Underwriter using such term sheet shall notify
the Company, and provide a copy of such term sheet to the Company, prior to, or substantially
concurrently with, the first use of such term sheet.
6. Conditions of Underwriters’ Obligations. The obligation of each Underwriter to
purchase the Underwritten Shares on the Closing Date or the Option Shares on the Additional Closing
Date, as the case may be, as provided herein is subject to the performance by the Company of its
covenants and other obligations hereunder and to the following additional conditions:
(a) Registration Compliance; No Stop Order. No order suspending the effectiveness of the
Registration Statement shall be in effect, and no proceeding for such purpose or pursuant to
Section 8A under the Securities Act shall be pending before or threatened by the Commission; the
Prospectus and each Issuer Free Writing Prospectus shall have been timely filed with the Commission
under the Securities Act (in the case of an Issuer Free Writing Prospectus, to the extent required
by Rule 433 under the Securities Act) and in accordance with Section 4(a) hereof; and all requests
by the Commission for additional information shall have been complied with to the reasonable
satisfaction of the Representatives.
(b) Representations and Warranties. The respective representations and warranties of the
Company contained herein shall be true and correct on the date hereof and on and as of the Closing
Date or the Additional Closing Date, as the case may be (except to the extent that such
representations and warranties speak as of another date, in which case such representations and
warranties shall be true and correct as of such other date); and the statements of the Company and
its officers made in any certificates delivered pursuant to this Agreement shall be true and
correct on and as of the Closing Date or the Additional Closing Date, as the case may be (except to
the extent that such representations and warranties speak as of another date, in which case such
representations and warranties shall be true and correct as of such other date).
(c) No Downgrade. Subsequent to the earlier of (A) the Applicable Time and (B) the execution
and delivery of this Agreement, if there are any debt securities or preferred stock of or
guaranteed by the Company or any of its subsidiaries that are rated by a “nationally recognized
statistical rating organization”, as such term is defined by the Commission for purposes of Rule
436(g)(2) under the Securities Act, (i) no downgrading shall have occurred in the rating accorded
any such debt securities or preferred stock and (ii) no such organization shall have publicly
announced that it has under surveillance or review, or has changed its outlook with respect to, its
rating of any such debt securities or preferred stock (other than an announcement with positive
implications of a possible upgrading).
22
(d) No Material Adverse Change. No event or condition of a type described in Section 3(f)
hereof shall have occurred or shall exist, which event or condition is not described in the Pricing
Disclosure Package (excluding any amendment or supplement thereto) and the Prospectus (excluding
any amendment or supplement thereto) and the effect of which in the judgment of the Representatives
makes it impracticable or inadvisable to proceed with the offering, sale or delivery of the Shares
on the Closing Date or the Additional Closing Date, as the case may be, on the terms and in the
manner contemplated by this Agreement, the Pricing Disclosure Package and the Prospectus.
(e) Officers’ Certificate. The Representatives shall have received on and as of the Closing
Date or the Additional Closing Date, as the case may be, a certificate of the chief financial
officer or chief accounting officer of the Company and one additional senior executive officer of
the Company who is satisfactory to the Representatives (i) confirming that such officers have
carefully reviewed the Registration Statement, the Pricing Disclosure Package and the Prospectus
and, to the best knowledge of such officers, the representations of the Company set forth in
Sections 3(b) and 3(d) hereof are true and correct, (ii) confirming that the other representations
and warranties of the Company in this Agreement are true and correct and that the Company has
complied in all material respects with all agreements and satisfied all conditions on its part to
be performed or satisfied hereunder at or prior to the Closing Date or the Additional Closing Date,
as the case may be, and (iii) to the effect set forth in paragraphs (a), (c) and (d) above.
(f) Comfort Letters. On the date of this Agreement and on the Closing Date or the Additional
Closing Date, as the case may be, Deloitte & Touche LLP shall have furnished to the
Representatives, at the request of the Company, letters, dated the respective dates of delivery
thereof and addressed to the Underwriters, in form and substance reasonably satisfactory to the
Representatives, containing statements and information of the type customarily included in
accountants’ “comfort letters” to underwriters with respect to the financial statements and certain
financial information contained in the Registration Statement, the Pricing Disclosure Package and
the Prospectus; provided, that the letter delivered on the Closing Date or the Additional Closing
Date, as the case may be, shall use a “cut-off” date no more than three business days prior to such
Closing Date or such Additional Closing Date, as the case may be.
(g) Opinion and 10b-5 Statement of Counsel for the Company. Faegre & Xxxxxx LLP, counsel for
the Company, shall have furnished to the Representatives, at the request of the Company, their
written opinion and 10b-5 statement, dated the Closing Date or the Additional Closing Date, as the
case may be, and addressed to the Underwriters, in form and substance reasonably satisfactory to
the Representatives, to the effect set forth in Annex A-1 hereto.
(h) Opinion of Internal Counsel for the Company. Xxxxx Street, internal counsel for the
Company, shall have furnished to the Representatives, her written opinion, dated the Closing Date
or the Additional Closing Date, as the case may be, and addressed to the Underwriters, in form and
substance reasonably satisfactory to the Representatives, to the effect set forth in Annex A-2
hereto.
(i) Opinion and 10b-5 Statement of Counsel for the Underwriters. The Representatives shall
have received on and as of the Closing Date or the Additional Closing
23
Date, as the case may be, an opinion and 10b-5 statement of Xxxxxx Xxxxxxxx Xxxxx & Xxxxxxxx
LLP, counsel for the Underwriters, with respect to such matters as the Representatives may
reasonably request, and such counsel shall have received such documents and information as they may
reasonably request to enable them to pass upon such matters.
(j) No Legal Impediment to Issuance and/or Sale. No action shall have been taken and no
statute, rule, regulation or order shall have been enacted, adopted or issued by any federal, state
or foreign governmental or regulatory authority that would, as of the Closing Date or the
Additional Closing Date, as the case may be, prevent the issuance or sale of the Shares by the
Company; and no injunction or order of any federal, state or foreign court shall have been issued
that would, as of the Closing Date or the Additional Closing Date, as the case may be, prevent the
issuance or sale of the Shares by the Company.
(k) Good Standing. The Representatives shall have received on and as of the Closing Date or
the Additional Closing Date, as the case may be, satisfactory evidence of the good standing of the
Company and its subsidiaries in their respective jurisdictions of organization and their good
standing as foreign entities in such other jurisdictions as the Representatives may reasonably
request, in each case in writing or any standard form of telecommunication from the appropriate
governmental authorities of such jurisdictions.
(l) Exchange Listing. The Shares to be delivered on the Closing Date or Additional Closing
Date, as the case may be, shall have been approved for listing on the Nasdaq Global Select Market,
subject to official notice of issuance.
(m) Lock-up Agreements. Lock-up Agreements, in form and substance satisfactory to you, as
Representatives, between Xxxxx Xxxxxxx & Co. and the parties listed on Annex D hereto relating to
sales and certain other dispositions of shares of Common Stock or certain other securities,
delivered to Xxxxx Xxxxxxx & Co. on or before the date hereof, shall be in full force and effect on
the Closing Date or Additional Closing Date, as the case may be.
(n) FINRA. FINRA shall have raised no objection to the fairness and reasonableness of the
underwriting terms and arrangements.
(o) Additional Documents. On or prior to the Closing Date or the Additional Closing Date, as
the case may be, the Company shall have furnished to the Representatives such further certificates
and documents as the Representatives may reasonably request.
(p) Additional Actions. The Company shall have (i) amended any outstanding warrants to
purchase shares of its Series A preferred stock to provide for conversion of such warrants into
warrants to purchase shares of common stock, (ii) amended its outstanding warrants that provide for
any put rights to eliminate such put rights upon the closing of the sale of shares contemplated
hereby, as described or contemplated in the Pricing Disclosure Package; (iii) entered into any
other amendment of its outstanding warrants as contemplated in the Pricing Disclosure Package; and
(iv) entered into an amendment which results in the termination of (A) Section 11 of the Amended
and Restated Investor Rights Agreement, dated as of May 15, 2008 (as such agreement may be amended
from time to time, the “Investor Rights Agreement”) and (B) the Amended and Restated Stockholders
Agreement, dated as of May 15, 2008 (as such
24
agreement may be amended from time to time, the “Stockholders Agreement”), in each case upon
the closing of the sale of shares contemplated hereby, as described or contemplated in the Pricing
Disclosure Package. The Company shall have also obtained waivers from (x) all stockholders of
their piggy back registration rights pursuant to Section 3 of the Investor Rights Agreement and (y)
the Required Holders (as such term is defined in the Stockholders Agreement), on behalf of the
holders of preemptive rights pursuant to the Stockholders Agreement of such preemptive rights.
(q) Trustee Release. Xxxxxxx X. Xxxxxx, in his capacity as receiver for, among others, Xxxxxx
X. Xxxxxxx (“Xxxxxxx”) and various entities owned or controlled by Petters, including EBP Select
Holdings, LLC, a Delaware limited liability company, and RTB Holding, LLC, a Delaware limited
liability company, and in his capacity as Chapter 11 trustee for Petters Group Worldwide, LLC, a
Delaware limited liability company, and of various other entities related to Petters that are also
the subject of Chapter 11 bankruptcy, or his duly appointed successor as receiver or trustee, shall
have granted a release of claims against (i) the Company, (ii) the Company’s wholly-owned
subsidiaries, (iii) certain of the Company’s current and former members of the board of directors,
officers and holders of the Company’s capital stock or warrants and (iv) the Underwriters,
substantially in the form of release filed in In re Petters Company Inc. et al. before the United
States Bankruptcy Court for the District of Minnesota on April 21, 2011.
All opinions, letters, certificates and evidence mentioned above or elsewhere in this
Agreement shall be deemed to be in compliance with the provisions hereof only if they are in form
and substance reasonably satisfactory to counsel for the Underwriters.
If any of the conditions hereinabove provided for in this Section 6 shall not have been
fulfilled when and as required by this Agreement to be fulfilled, the obligations of the
Underwriters hereunder may be terminated by the Representatives by notifying the Company of such
termination in writing at or prior to the Closing Date or the Additional Closing Date, as the case
may be.
In such event, the Company and the Underwriters shall not be under any obligation to each
other (except to the extent provided in Sections 7 and 11 hereof).
7. Indemnification and Contribution.
(a) Indemnification of the Underwriters. The Company agrees to indemnify and hold harmless
each Underwriter, its affiliates, directors and officers and each person, if any, who controls such
Underwriter within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange
Act, from and against any and all losses, claims, damages and liabilities (including, without
limitation, legal fees and other expenses incurred in connection with any suit, action or
proceeding or any claim asserted, as such fees and expenses are incurred), joint or several, that
arise out of, or are based upon, (i) any untrue statement or alleged untrue statement of a material
fact contained in the Registration Statement or caused by any omission or alleged omission to state
therein a material fact required to be stated therein or necessary in order to make the statements
therein, not misleading, (ii) or any untrue statement or alleged untrue statement of a material
fact contained in the Prospectus (or any amendment or supplement thereto), any Issuer Free Writing
Prospectus, any “issuer information” filed or required to be
25
filed pursuant to Rule 433(d) under the Securities Act or any Pricing Disclosure Package
(including any Pricing Disclosure Package that has subsequently been amended), or caused by any
omission or alleged omission to state therein a material fact necessary in order to make the
statements therein, in light of the circumstances under which they were made, not misleading, in
each case except insofar as such losses, claims, damages or liabilities arise out of, or are based
upon, any untrue statement or omission or alleged untrue statement or omission made in reliance
upon and in conformity with any information furnished to the Company in writing by any Underwriter
through the Representatives expressly for use therein, it being understood and agreed that the only
such information furnished by any Underwriter consists of the information described as such in
subsection (b) below.
(b) Indemnification of the Company. Each Underwriter agrees, severally and not jointly, to
indemnify and hold harmless the Company, its directors, its officers who signed the Registration
Statement and each person, if any, who controls the Company within the meaning of Section 15 of the
Securities Act or Section 20 of the Exchange Act but only with respect to any losses, claims,
damages or liabilities that arise out of, or are based upon, any untrue statement or omission or
alleged untrue statement or omission made in reliance upon and in conformity with any information
relating to such Underwriter furnished to the Company in writing by such Underwriter through the
Representatives expressly for use in the Registration Statement, the Prospectus (or any amendment
or supplement thereto), any Issuer Free Writing Prospectus or any Pricing Disclosure Package, it
being understood and agreed upon that the only such information furnished by any Underwriter
consists of the following information in the Prospectus furnished on behalf of each Underwriter:
the concession and reallowance figures appearing in the third paragraph under the caption
“Underwriting,” and the information contained in the eleventh through sixteenth paragraphs under
the caption “Underwriting.”
(c) Notice and Procedures. If any suit, action, proceeding (including any governmental or
regulatory investigation), claim or demand shall be brought or asserted against any person in
respect of which indemnification may be sought pursuant to the preceding paragraphs of this Section
7, such person (the “Indemnified Person”) shall promptly notify the person against whom such
indemnification may be sought (the “Indemnifying Person”) in writing; provided that the
failure to notify the Indemnifying Person shall not relieve it from any liability that it may have
under the preceding paragraphs of this Section 7 except to the extent that it has been materially
prejudiced (through the material impairment or forfeiture of substantive rights or defenses) by
such failure; and provided further that the failure to notify the Indemnifying Person shall
not relieve it from any liability that it may have to an Indemnified Person otherwise than under
the preceding paragraphs of this Section 7. If any such proceeding shall be brought or asserted
against an Indemnified Person and it shall have notified the Indemnifying Person thereof, the
Indemnifying Person shall retain counsel reasonably satisfactory to the Indemnified Person (who
shall not, without the consent of the Indemnified Person, be counsel to the Indemnifying Person) to
represent the Indemnified Person in such proceeding and shall pay the fees and expenses of such
counsel related to such proceeding, as incurred. In any such proceeding, any Indemnified Person
shall have the right to retain its own counsel, but the fees and expenses of such counsel shall be
at the expense of such Indemnified Person unless (i) the Indemnifying Person and the Indemnified
Person shall have mutually agreed to the contrary; (ii) the Indemnifying Person has failed within a
reasonable time to retain counsel reasonably satisfactory to the Indemnified Person; (iii) the
Indemnified Person shall have reasonably concluded that
26
there may be legal defenses available to it that are different from or in addition to those
available to the Indemnifying Person; or (iv) the named parties in any such proceeding (including
any impleaded parties) include both the Indemnifying Person and the Indemnified Person and
representation of both parties by the same counsel would be inappropriate due to actual or
potential differing interest between them. It is understood and agreed that the Indemnifying
Person shall not, in connection with any proceeding or related proceedings in the same
jurisdiction, be liable for the fees and expenses of more than one separate firm (in addition to
any local counsel) for all Indemnified Persons, and that all such fees and expenses shall be paid
or reimbursed as they are incurred upon receipt from the Indemnified Person of a written request
for payment thereof accompanied by a written statement with reasonable supporting detail of such
fees and expenses. Any such separate firm for any Underwriter, its affiliates, directors and
officers and any control persons of such Underwriter shall be designated in writing by such
Underwriter, any such separate firm for the Company, its directors, its officers who signed the
Registration Statement and any control persons of the Company shall be designated in writing by the
Company. The Indemnifying Person shall not be liable for any settlement of any proceeding effected
without its written consent, but if settled with such consent or if there be a final judgment for
the plaintiff, the Indemnifying Person agrees to indemnify each Indemnified Person from and against
any loss or liability by reason of such settlement or judgment. Notwithstanding the foregoing
sentence, if at any time an Indemnified Person shall have requested that an Indemnifying Person
reimburse the Indemnified Person for reasonably incurred fees and expenses of counsel in accordance
with this paragraph, the Indemnifying Person shall be liable for any settlement of any proceeding
effected without its written consent if (i) such settlement is entered into (A) more than 60 days
after receipt by the Indemnifying Person of such request in writing, and (B) more than 30 days
after receipt by the Indemnifying Person of the proposed terms of such settlement in writing, and
(ii) the Indemnifying Person shall not have reimbursed the Indemnified Person in accordance with
such request prior to the date of such settlement. No Indemnifying Person shall, without the
written consent of the Indemnified Person, effect any settlement of any pending or threatened
proceeding in respect of which any Indemnified Person is or could have been a party and
indemnification could have been sought hereunder by such Indemnified Person, unless such settlement
(x) includes an unconditional release of such Indemnified Person, in form and substance reasonably
satisfactory to such Indemnified Person, from all liability on claims that are the subject matter
of such proceeding and (y) does not include any statement as to or any admission of fault,
culpability or a failure to act by or on behalf of any Indemnified Person.
(d) Contribution. If the indemnification provided for in paragraphs (a), (b) or (c) above is
unavailable to an Indemnified Person or insufficient in respect of any losses, claims, damages or
liabilities referred to therein, then each Indemnifying Person under such paragraph, in lieu of
indemnifying such Indemnified Person thereunder, shall contribute to the amount paid or payable by
such Indemnified Person as a result of such losses, claims, damages or liabilities (i) in such
proportion as is appropriate to reflect the relative benefits received by the Company, on the one
hand, and the Underwriters, on the other, from the offering of the Shares or (ii) if the allocation
provided by clause (i) is not permitted by applicable law, in such proportion as is appropriate to
reflect not only the relative benefits referred to in clause (i) but also the relative fault of the
Company, on the one hand, and the Underwriters, on the other, in connection with the statements or
omissions that resulted in such losses, claims, damages or liabilities, as well as any other
relevant equitable considerations. The relative benefits received by the Company, on
27
the one hand, and the Underwriters, on the other, shall be deemed to be in the same respective
proportions as the net proceeds (before deducting expenses) received by the Company from the sale
of the Shares and the total underwriting discounts and commissions received by the Underwriters in
connection therewith, in each case as set forth in the table on the cover of the Prospectus, bear
to the aggregate offering price of the Shares. The relative fault of the Company, on the one hand,
and the Underwriters, on the other, shall be determined by reference to, among other things,
whether the untrue or alleged untrue statement of a material fact or the omission or alleged
omission to state a material fact relates to information supplied by the Company or by the
Underwriters, and the parties’ relative intent, knowledge, access to information and opportunity to
correct or prevent such statement or omission.
(e) Limitation on Liability. The Company and the Underwriters agree that it would not be just
and equitable if contribution pursuant to this Section 7 were determined by pro
rata allocation (even if the Underwriters were treated as one entity for such purpose) or
by any other method of allocation that does not take account of the equitable considerations
referred to in paragraph (d) above. The amount paid or payable by an Indemnified Person as a
result of the losses, claims, damages and liabilities referred to in paragraph (d) above shall be
deemed to include, subject to the limitations set forth above, any legal or other expenses
reasonably incurred by such Indemnified Person in connection with any such action or claim.
Notwithstanding the provisions of this Section 7, in no event shall an Underwriter be required to
contribute any amount in excess of the amount by which the total underwriting discounts and
commissions received by such Underwriter with respect to the offering of the Shares exceeds the
amount of any damages that such Underwriter has otherwise been required to pay by reason of such
untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent
misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to
contribution from any person who was not guilty of such fraudulent misrepresentation. The
Underwriters’ obligations to contribute pursuant to this Section 7 are several in proportion to
their respective purchase obligations hereunder and not joint.
(f) Non-Exclusive Remedies. The remedies provided for in this Section 7 are not exclusive and
shall not limit any rights or remedies which may otherwise be available to any Indemnified Person
at law or in equity.
8. Effectiveness of Agreement. This Agreement shall become effective upon the
execution and delivery hereof by the parties hereto.
9. Termination. This Agreement may be terminated in the absolute discretion of the
Representatives, by written notice to the Company:
(a) if after the execution and delivery of this Agreement and prior to the Closing Date or, in
the case of the Option Shares, prior to the Additional Closing Date (i) trading generally shall
have been suspended or materially limited on or by any of the New York Stock Exchange, the American
Stock Exchange, The Nasdaq Market, the Chicago Board Options Exchange, the Chicago Mercantile
Exchange or the Chicago Board of Trade; (ii) trading of any securities issued or guaranteed by the
Company shall have been suspended on any exchange or in any over-the-counter market; (iii) a
general moratorium on commercial banking activities shall have been declared by federal or New York
State authorities; or (iv) there shall have occurred
28
any outbreak or escalation of hostilities or any change in financial markets or any calamity
or crisis, either within or outside the United States, that, in the judgment of the
Representatives, is material and adverse and makes it impracticable or inadvisable to proceed with
the offering, sale or delivery of the Shares on the Closing Date or the Additional Closing Date, as
the case may be, on the terms and in the manner contemplated by this Agreement, the Pricing
Disclosure Package and the Prospectus, or
(b) as provided in Sections 6 and 10 of this Agreement.
10. Defaulting Underwriter.
(a) If, on the Closing Date or the Additional Closing Date, as the case may be, any
Underwriter defaults on its obligation to purchase the Shares that it has agreed to purchase
hereunder on such date, the non-defaulting Underwriters may in their discretion arrange for the
purchase of such Shares by other persons satisfactory to the Company on the terms contained in this
Agreement. If, within 36 hours after any such default by any Underwriter, the non-defaulting
Underwriters do not arrange for the purchase of such Shares, then the Company shall be entitled to
a further period of 36 hours within which to procure other persons reasonably satisfactory to the
non-defaulting Underwriters to purchase such Shares on such terms. If other persons become
obligated or agree to purchase the Shares of a defaulting Underwriter, either the non-defaulting
Underwriters or the Company may postpone the Closing Date or the Additional Closing Date, as the
case may be, for up to five full business days in order to effect any changes that in the opinion
of counsel for the Company, or counsel for the Underwriters may be necessary in the Registration
Statement and the Prospectus or in any other document or arrangement, and the Company agrees to
promptly prepare any amendment or supplement to the Registration Statement and the Prospectus that
effects any such changes. As used in this Agreement, the term “Underwriter” includes, for all
purposes of this Agreement unless the context otherwise requires, any person not listed in Schedule
I hereto that, pursuant to this Section 10, purchases Shares that a defaulting Underwriter agreed
but failed to purchase.
(b) If, after giving effect to any arrangements for the purchase of the Shares of a defaulting
Underwriter or Underwriters by the non-defaulting Underwriters and the Company, as provided in
paragraph (a) above, the aggregate number of Shares that remain unpurchased on the Closing Date or
the Additional Closing Date, as the case may be, does not exceed one-eleventh of the aggregate
number of Shares to be purchased on such date, then the Company shall have the right to require
each non-defaulting Underwriter to purchase the number of Shares that such Underwriter agreed to
purchase hereunder on such date plus such Underwriter’s pro rata share (based on the number of
Shares that such Underwriter agreed to purchase on such date) of the Shares of such defaulting
Underwriter or Underwriters for which such arrangements have not been made.
(c) If, after giving effect to any arrangements for the purchase of the Shares of a defaulting
Underwriter or Underwriters by the non-defaulting Underwriters and the Company, as provided in
paragraph (a) above, the aggregate number of Shares that remain unpurchased on the Closing Date or
the Additional Closing Date, as the case may be, exceeds one-eleventh of the aggregate amount of
Shares to be purchased on such date, or if the Company shall not exercise the right described in
paragraph (b) above, then this Agreement or, with respect to any
29
Additional Closing Date, the obligation of the Underwriters to purchase Shares on the
Additional Closing Date, shall terminate without liability on the part of the non-defaulting
Underwriters. Any termination of this Agreement pursuant to this Section 10 shall be without
liability on the part of the Company, except that the Company will continue to be liable for the
payment of expenses as set forth in Section 11 hereof and except that the provisions of Section 7
hereof shall not terminate and shall remain in effect.
(d) Nothing contained herein shall relieve a defaulting Underwriter of any liability it may
have to the Company or any non-defaulting Underwriter for damages caused by its default.
11. Payment of Expenses.
(a) Whether or not the transactions contemplated by this Agreement are consummated or this
Agreement is terminated, and subject to Section 11(b), the Company will pay or cause to be paid all
costs and expenses incident to the performance of its obligations hereunder, including without
limitation, (i) the costs incident to the authorization, issuance, sale, preparation and delivery
of the Shares and any taxes payable by the Company in that connection; (ii) the costs incident to
the preparation, printing and filing under the Securities Act of the Registration Statement, the
Preliminary Prospectus, any Issuer Free Writing Prospectus, any Pricing Disclosure Package and the
Prospectus (including all exhibits, amendments and supplements thereto) and the distribution
thereof; (iii) the fees and expenses of the Company’s counsel and independent accountants; (iv) the
reasonable fees and expenses incurred in connection with the registration or qualification and
determination of eligibility for investment of the Shares under the state or foreign securities or
blue sky laws of such jurisdictions as the Representatives may designate and the preparation,
printing and distribution of a Blue Sky Memorandum (including the related fees and expenses of
counsel for the Underwriters up to $5,000); (v) the cost of preparing stock certificates; (vi) the
costs and charges of any transfer agent and any registrar; (vii) all expenses and application fees
incurred in connection with any filing with, and clearance of the offering by, FINRA (including the
related fees and expenses of counsel for the Underwriters up to an aggregate of $20,000); (viii)
all expenses incurred by the Company in connection with any “road show” presentation to potential
investors (it being agreed that, notwithstanding anything herein to the contrary, the Company, on
the one hand, and the Underwriters, on the other hand, shall each bear half of the costs associated
with any private aircraft chartered in connection with such presentation); and (ix) all expenses
and application fees related to the listing of the Shares on the Nasdaq Market. It is agreed that,
except as specifically provided in this Section 11, the Underwriters will pay all of their own
costs and expenses, including the fees of their counsel, stock transfer taxes on the resale of any
Shares by the Underwriters, and any advertising expenses in connection with the offering
contemplated by this Agreement.
(b) If (i) this Agreement is terminated pursuant to Section 11, (ii) the Company for any
reason fails to tender the Shares for delivery to the Underwriters or (iii) the Underwriters
decline to purchase the Shares for any reason permitted under this Agreement, the Company agrees to
reimburse the Underwriters for all documented out-of-pocket costs and expenses (including the fees
and expenses of their counsel) reasonably incurred by the Underwriters in connection with this
Agreement and the offering contemplated hereby.
30
12. Persons Entitled to Benefit of Agreement. This Agreement shall inure to the
benefit of and be binding upon the parties hereto and their respective successors and the officers
and directors and any controlling persons referred to in Section 7 hereof. Nothing in this
Agreement is intended or shall be construed to give any other person any legal or equitable right,
remedy or claim under or in respect of this Agreement or any provision contained herein. No
purchaser of Shares from any Underwriter shall be deemed to be a successor merely by reason of such
purchase.
13. Survival. The respective indemnities, rights of contribution, representations,
warranties and agreements of the Company and the Underwriters contained in this Agreement or made
by or on behalf of the Company or the Underwriters pursuant to this Agreement or any certificate
delivered pursuant hereto shall survive the delivery of and payment for the Shares and shall remain
in full force and effect, regardless of any termination of this Agreement or any investigation made
by or on behalf of the Company or the Underwriters.
14. Certain Defined Terms. For purposes of this Agreement, (a) except where otherwise
expressly provided, the term “affiliate” has the meaning set forth in Rule 405 under the Securities
Act; (b) the term “business day” means any day other than a day on which banks are permitted or
required to be closed in New York City; and (c) the term “subsidiary” has the meaning set forth in
Rule 405 under the Securities Act.
15. Miscellaneous.
(a) Authority of the Representatives. Any action by the Underwriters hereunder may be taken
by Xxxxx Xxxxxxx & Co. and Xxxxx Fargo Securities, LLC on behalf of the Underwriters, and any such
action taken by Xxxxx Xxxxxxx & Co. and Xxxxx Fargo Securities, LLC shall be binding upon the
Underwriters.
(b) Notices. All notices and other communications hereunder shall be in writing and shall be
deemed to have been duly given if mailed or transmitted and confirmed by any standard form of
telecommunication. Notices to the Underwriters shall be given to the Representatives c/o Xxxxx
Xxxxxxx & Co., 000 Xxxxxxxx Xxxx, Xxxxxxxxxxx, Xxxxxxxxx 00000, Attention: Equity Capital Markets
(Fax: (000) 000-0000), with a copy to Legal Department (Fax: (000) 000-0000), and Xxxxx Fargo
Securities, LLC, 000 Xxxx Xxxxxx, 0xx Xxxxx, Xxx Xxxx, Xxx Xxxx 00000, Attention: Equity
Syndicate Department (Fax: (000) 000-0000). Notices to the Company shall be given to it at 0000
Xxxxxx Xxxxx Xxxxx, Xxxx Xxxxxxx, XX 00000, Attention: Chief Financial Officer (Fax: (000)
000-0000).
(c) Governing Law. This Agreement and any claim, controversy or dispute arising under or
related to this Agreement shall be governed by and construed in accordance with the laws of the
State of New York applicable to agreements made and to be performed in such state.
(d) Counterparts. This Agreement may be signed in counterparts (which may include
counterparts delivered by any standard form of telecommunication), each of which shall be an
original and all of which together shall constitute one and the same instrument.
31
(e) Amendments or Waivers. No amendment or waiver of any provision of this Agreement, nor any
consent or approval to any departure therefrom, shall in any event be effective unless the same
shall be in writing and signed by the parties hereto.
(f) Headings. The headings herein are included for convenience of reference only and are not
intended to be part of, or to affect the meaning or interpretation of, this Agreement.
32
If the foregoing is in accordance with your understanding, please indicate your acceptance of
this Agreement by signing in the space provided below.
Very truly yours, BLUESTEM BRANDS, INC. |
||||
By: | ||||
Name: | ||||
Title: | ||||
Bluestem Brands Underwriting Agreement — Signature Page
Accepted: __________, 2011
XXXXX XXXXXXX & CO.
For itself and on behalf of the
several Underwriters listed
in Schedule I hereto.
several Underwriters listed
in Schedule I hereto.
By: | ||||
Authorized Signatory | ||||
By: | ||||
Authorized Signatory | ||||
XXXXX FARGO SECURITIES, LLC
For itself and on behalf of the
several Underwriters listed
in Schedule I hereto.
several Underwriters listed
in Schedule I hereto.
By: | ||||
Authorized Signatory | ||||
By: | ||||
Authorized Signatory | ||||
Bluestem Brands Underwriting Agreement — Signature Page
Schedule I
Underwriter | Number of Underwritten Shares | |||
Xxxxx Xxxxxxx & Co. |
||||
Xxxxx Fargo Securities, LLC |
||||
Deutsche Bank Securities Inc. |
||||
Xxxxxxxxxxx & Co. Inc. |
||||
Xxxxxxx Xxxxx & Co., LLC |
||||
Total |
10,000,000 |
Schedule I
Annex A-1
[Form of Opinion of Counsel for the Company]
(-) The Registration Statement was declared effective under the Securities Act as of the date
and time specified in such opinion; each of the Preliminary Prospectus and the Prospectus was filed
with the Commission pursuant to the subparagraph of Rule 424(b) under the Securities Act specified
in such opinion on the date specified therein; and, to the knowledge of such counsel, no order
suspending the effectiveness of the Registration Statement has been issued and no proceeding for
that purpose or pursuant to Section 8A of the Securities Act against the Company or in connection
with the offering is pending or threatened by the Commission.
(-) The Registration Statement and the Prospectus, as of their respective effective or issue
dates (other than the financial statements and related schedules and financial data therein, as to
which such counsel need express no opinion), comply as to form in all material respects with the
requirements of the Securities Act.
(-) The Company and each of its subsidiaries have been duly incorporated (or, in the case of
limited liability companies, duly formed) and are validly existing and in good standing under the
laws of their respective jurisdictions of organization, are duly qualified to do business and are
in good standing in [name jurisdictions], and have all corporate power and authority necessary to
own or hold their respective properties and to conduct the businesses in which they are engaged as
described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, except
where the failure to be so qualified or have such power or authority would not, individually or in
the aggregate, have a Material Adverse Effect.
(-) The Company has an authorized capitalization as set forth in the Registration Statement,
the Pricing Disclosure Package and the Prospectus under the heading “Capitalization;” all the
outstanding shares of capital stock of the Company have been duly and validly authorized and issued
and are fully paid and non-assessable; the capital stock of the Company conforms in all material
respects to the description thereof contained in the Registration Statement, the Pricing Disclosure
Package and the Prospectus, and except as otherwise stated in the Registration Statement, the
Pricing Disclosure Package and the Prospectus, there are no preemptive or similar rights with
respect to any shares of capital stock of the Company that may hereafter be issued or sold by the
Company pursuant to the Company’s charter, by-laws or (i) any agreement or instrument included as
an exhibit to the Registration Statement, or (ii) any other agreement or instrument identified on a
Schedule to this opinion (each such agreement or instrument contemplated by clause (i) or (ii), a
“Specified Contract”); all the outstanding shares of capital stock or other equity interests of
each subsidiary owned, directly or indirectly, by the Company have been duly and validly authorized
and issued, are fully paid and non-assessable; and except as otherwise stated in the Registration
Statement, the Pricing Disclosure Package and the Prospectus, to such counsel’s knowledge, the
outstanding shares of capital stock of each of the subsidiaries is owned free and clear of all
liens, encumbrances and equities and claims, and no options, warrants or other rights to purchase,
agreements or other
Annex A-1-1
obligations to issue or other rights to convert any obligations into any shares of capital
stock or of ownership interests in the subsidiaries are outstanding.
(-) The Company has full corporate right, power and authority to execute and deliver the
Underwriting Agreement and to perform its obligations thereunder; and all corporate action required
to be taken for the due and proper authorization, execution, delivery and performance by the
Company of the Underwriting Agreement has been duly and validly taken.
(-) The Underwriting Agreement has been duly authorized, executed and delivered by the
Company.
(-) The Underwritten Shares to be issued and sold by the Company hereunder have been duly
authorized, and when delivered to and paid for by the Underwriters in accordance with the terms of
the Underwriting Agreement, will be validly issued, fully paid and non-assessable and, except for
rights set forth in the Stockholders Agreement that have been satisfied or waived, the issuance of
the Underwritten Shares is not subject to any preemptive or similar rights under the Delaware
General Corporation Law, the Company’s certificate of incorporation or by-laws, or any Specified
Contract.
(-) The execution, delivery and performance by the Company of the Underwriting Agreement and
the issuance and sale of the Underwritten Shares being delivered on the Closing Date will not (i)
result in a breach or violation of any of the terms or provisions of, or constitute a default
under, or result in the creation or imposition of any lien, charge or encumbrance upon any property
or assets of the Company or any of its subsidiaries pursuant to, any Specified Contract, (ii)
result in any violation of the provisions of the certificate of incorporation or by-laws or similar
organizational documents of the Company or any of its subsidiaries, (iii) result in the violation
of any law, statute or regulation of any governmental or regulatory authority or (iv) result in the
violation of any judgment or order listed on Schedule [ ] hereto.
(-) No consent, approval, authorization, order, registration or qualification of or with any
court or arbitrator or governmental or regulatory authority is required for the execution, delivery
and performance by the Company of the Underwriting Agreement and the issuance and sale by the
Company of the Underwritten Shares being delivered on the Closing Date, except for the registration
of the Shares under the Securities Act and such consents, approvals, authorizations, orders and
registrations or qualifications as may be required under applicable state or foreign securities
laws in connection with the purchase and distribution of the Shares by the Underwriters.
(-) The descriptions in the Registration Statement, the Pricing Disclosure Package and the
Prospectus of statutes, legal, governmental and regulatory proceedings and contracts and other
documents are accurate in all material respects; the statements in the Preliminary Prospectus and
Prospectus under the headings “Material U.S. Federal Income and Estate Tax Considerations to
Non-U.S. Holders,” “Description of Capital Stock,” and “Underwriting” (to the extent that the
statements under such heading summarize the provisions of U.S. federal laws and documents to which
the Company is a party), and in the Registration Statement in Items 14 and 15, to the extent that
they constitute summaries of the terms of stock, matters of law or regulation or legal conclusions,
fairly summarize the matters described therein in all material
Annex A-1-2
respects; and, to the knowledge of such counsel, (A) there are no current or pending legal,
governmental or regulatory actions, suits or proceedings that are required under the Securities Act
to be described in the Registration Statement or the Prospectus and that are not so described in
the Registration Statement, the Pricing Disclosure Package and the Prospectus and (B) there are no
statutes, regulations or contracts and other documents that are required under the Securities Act
to be filed as exhibits to the Registration Statement or described in the Registration Statement or
the Prospectus and that have not been so filed as exhibits to the Registration Statement or
described in the Registration Statement, the Pricing Disclosure Package and the Prospectus.
(-) After giving effect to the application of the proceeds received by the Company from the
offering and sale of the Underwritten Shares, as described in the Registration Statement, the
Pricing Disclosure Package and the Prospectus, the Company will not be required to register as an
“investment company” or an entity “controlled” by an “investment company” within the meaning of the
Investment Company Act.
(-) Any required filing of each Issuer Free Writing Prospectus pursuant to Rule 433 under the
Securities Act has been made within the time period required by Rule 433(d) under the Securities
Act.
Such counsel shall also state that they have reviewed corporate and other materials of the
Company and participated in conferences with representatives of the Company and with
representatives of its independent accountants and counsel at which conferences the contents of the
Registration Statement, the Pricing Disclosure Package and the Prospectus and any amendment and
supplement thereto and related matters were discussed and, although such counsel assume no
responsibility for the accuracy, completeness or fairness of the Registration Statement, the
Pricing Disclosure Package, the Prospectus and any amendment or supplement thereto (except as
expressly provided above), nothing has come to the attention of such counsel to cause such counsel
to believe that the Registration Statement, at the time of its effective date (including the
information, if any, deemed pursuant to Rule 430A, 430B or 430C to be part of the Registration
Statement at the time of effectiveness), contained any untrue statement of a material fact or
omitted to state a material fact required to be stated therein or necessary to make the statements
therein not misleading, that the Pricing Disclosure Package as of the Applicable Time (which such
counsel may assume to be the date of the Underwriting Agreement) contained any untrue statement of
a material fact or omitted to state a material fact necessary to make the statements therein, in
the light of the circumstances under which they were made, not misleading or that the Prospectus or
any amendment or supplement thereto as of its date and the Closing Date contains any untrue
statement of a material fact or omits to state a material fact necessary to make the statements
therein, in the light of the circumstances under which they were made, not misleading (other than
the financial statements, financial schedules and other financial information contained therein,
as to which such counsel need express no belief).
In rendering such opinion, such counsel may rely as to matters of fact on certificates of
responsible officers of the Company and public officials that are furnished to the Underwriters.
The opinion of Faegre & Xxxxxx LLP described above shall be rendered to the Underwriters at
the request of the Company and shall so state therein.
Annex X-0-0
Xxxxx X-0
[Form of Opinion of Internal Counsel for the Company]
(-) To the knowledge of such counsel, except as described in the Registration Statement, the
Pricing Disclosure Package and the Prospectus (i) there are no legal, governmental or regulatory
investigations, actions, suits or proceedings pending to which the Company or any of its
subsidiaries is or may be a party or to which any property of the Company or any of its
subsidiaries is or may be the subject which, individually or in the aggregate, if determined
adversely to the Company or any of its subsidiaries, could reasonably be expected to have a
Material Adverse Effect, and (ii) no such investigations, actions, suits or proceedings are
threatened or contemplated by any governmental or regulatory authority or threatened by others
which, individually or in the aggregate, if determined adversely to the Company or any of its
subsidiaries, could reasonably be expected to have a Material Adverse Effect.
Annex-A-2
Annex B
a. Pricing Disclosure Package
[each Issuer Free Writing Prospectus to be included in the Pricing Disclosure Package]
[b. Pricing Information Provided Orally by Underwriters]
Number of Underwritten Shares: [_______]
Number of Option Shares: [_______]
Public Offering Price (per share): $[______]
Underwriting Discount (per share): $[______]
Annex-B
Annex C
[Issuer Name]
Pricing Term Sheet
[Subject to Determination]
Annex-C
Annex D
1
|
Petters Group Worldwide, LLC | |
2
|
Battery Ventures VI, L.P. | |
3
|
Brookside Capital Partners Fund, L.P. | |
4
|
Xxxx Capital Venture Fund 2007, L.P. | |
5
|
Brookside Capital Partners Fund, L.P. | |
6
|
Xxxx Capital Venture Fund, L.P. | |
7
|
Xxxxx Xxxxx | |
8
|
Prudential Capital Partners II, L.P. | |
9
|
EBP Select Holdings, LLC | |
10
|
BCIP Venture Associates | |
11
|
Xxxxxxxx Xxxxxx as Trustee of the Xxxxxxxx Xxxxxx Family Term Trust, Established December 30, 2009 | |
12
|
BCIP Associates III, LLC | |
13
|
Xxxx Xxxxxx Trust | |
14
|
Battery Investment Partners VI, LLC | |
15
|
Xxxx Xxxxxxx | |
16
|
Xxxxxxx Xxxxxxxx | |
17
|
Battery Investment Partners VI, LLC | |
18
|
Prudential Capital Partners (Parallel Fund) II, L.P. | |
19
|
Chidam Chidambaram | |
20
|
Xxx X. Xxxxx | |
21
|
Xxxx Xxxxxxxx | |
22
|
CIGPF I Corp | |
23
|
Xxxxxxxxxx Xxxxxxxx | |
24
|
Xxxxx X. Xxxxxxx and Xxxxxxx X. Xxxxxxx, Trustees of the Xxxxx X. Xxxxxxx Revocable Trust Dated February 25, 2000 | |
25
|
Prudential Capital Partners Management Fund II, L.P. | |
26
|
Xxxx Xxxxxx | |
27
|
Xxx X. Xxxxxxx | |
28
|
RTB Holding, LLC | |
29
|
BCIP Associates III-B, LLC | |
00
|
Xxxxx Xxxxxx | |
31
|
BCIP Venture Associates B | |
32
|
Xxxx X. Xxxxxxxx | |
33
|
Xxxxxxx, Xxxxx & Co. | |
34
|
DB FHUT LLC | |
35
|
Prudential Capital Partners II, LP | |
36
|
CCP Credit Acquisition Holdings, LLC | |
37
|
Eton Park Fund, L.P. | |
38
|
FPF FHUT LLC | |
39
|
FCOF UB Investments LLC | |
40
|
Prudential Capital Partners (Parallel Fund) II, LP | |
41
|
Prudential Capital Partners Management Fund II, LP |
Annex-D
Annex E
[Form of Press Release]
[Company]
[Date]
[Date]
Bluestem Brands, Inc. (the “Company”) announced today that Xxxxx Xxxxxxx & Co., a representative of
the underwriters in the Company’s initial public sale of shares of common stock, is [waiving]
[releasing] a lock-up restriction with respect to shares of the Company’s common stock
held by [certain officers or directors] [an officer or director] of the Company. The [waiver]
[release] will take effect on , 20 , and the shares may be sold on or after such
date.
This press release is not an offer for sale of the securities in the United States or in any
other jurisdiction where such offer is prohibited, and such securities may not be offered or sold
in the United States absent registration or an exemption from registration under the United States
Securities Act of 1933, as amended
Annex-E